Home › NDC Lookup › RxCUI directory › RxCUI 153124

Letrozole 2.5 MG Oral Tablet [Femara] — RxCUI 153124

RxNorm drug concept · Semantic branded drug
RxCUI 153124 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI153124
Official nameLetrozole 2.5 MG Oral Tablet [Femara]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asFemara 2.5 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)48 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Letrozole: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Letrozole is not chemotherapy. It's a hormone therapy, specifically an aromatase inhibitor — it works by dramatically lowering estrogen levels in your body. Some breast cancers are...
  • What exactly is letrozole being used to treat — is it chemotherapy?
  • Good news — you can take letrozole with or without food, whichever is easiest for you. Meals don't affect how the medication is absorbed. As for timing, pick a time of day you'll r...
  • Can I take letrozole with food, and does it matter what time of day I take it?
📖 Read our full Letrozole guide →

🕸️ Concept Web — How Letrozole 2.5 MG Oral Tablet [Femara] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Letrozole 2.5 MG Oral Tablet [Femara] RxCUI 153124

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Letrozole 72965
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Femara 203769
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Letrozole Oral Tablet 372571
    • Letrozole Oral Product 1163195
    • Letrozole Pill 1163196
    • Letrozole Oral Tablet [Femara] 368318
    • Femara Oral Product 1176624
    • Femara Pill 1176625
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 6

    Fixed collections of drugs packaged and sold together, like dose packs.

    • {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 21 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 200] 1923054
    • {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 42 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 400] 1923056
    • {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 63 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 600] 1923058
    • {28 (letrozole 2.5 MG Oral Tablet) / 21 (ribociclib 200 MG Oral Tablet) } Pack 1923053
    • {28 (letrozole 2.5 MG Oral Tablet) / 42 (ribociclib 200 MG Oral Tablet) } Pack 1923055
    • {28 (letrozole 2.5 MG Oral Tablet) / 63 (ribociclib 200 MG Oral Tablet) } Pack 1923057

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Letrozole 2.5 MG Oral Tablet SCD · 200064
  • Letrozole 2.5 MG SCDC · 316135
  • Letrozole Oral Tablet SCDF · 372571
  • Letrozole Oral Product SCDG · 1163195
  • Letrozole Pill SCDG · 1163196
  • {28 (letrozole 2.5 MG Oral Tablet) / 21 (ribociclib 200 MG Oral Tablet) } Pack GPCK · 1923053
  • {28 (letrozole 2.5 MG Oral Tablet) / 42 (ribociclib 200 MG Oral Tablet) } Pack GPCK · 1923055
  • {28 (letrozole 2.5 MG Oral Tablet) / 63 (ribociclib 200 MG Oral Tablet) } Pack GPCK · 1923057

Brand-Name Concepts

  • Letrozole 2.5 MG [Femara] SBDC · 565177
  • Letrozole Oral Tablet [Femara] SBDF · 368318
  • Femara Oral Product SBDG · 1176624
  • Femara Pill SBDG · 1176625
  • Femara BN · 203769
  • {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 21 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 200] BPCK · 1923054
  • {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 42 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 400] BPCK · 1923056
  • {28 (letrozole 2.5 MG Oral Tablet [Femara]) / 63 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 600] BPCK · 1923058

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 153124 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0249-15 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0078-0249-15) Femara Novartis Pharmaceuticals Corporation 1997-07-31
Observed labelers: Novartis Pharmaceuticals Corporation (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$27.1160
Range $27.1160–$27.1160 · middle 50% $27.1160–$27.1160 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.